OPTUS Pharmaceutical

At a glance

OPTUS Pharmaceutical filed 24 disclosures in the last 12 months, including 1 insider and 1 buyback. The most recent key filing was on Jun 12.

Revenue for 2025 was ₩87.2B, up 6.4% on 2024. Operating margin was 10.2% against 10.5% a year earlier. Debt was 16% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩47.8B and operating profit of ₩5.2B.

The 2025 annual report lists 250 employees with an average tenure of 4 years and average pay of ₩54.2M, #1260 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩85M each on average. It paid no cash dividend for 2025. 삼천당제약(주) and related parties held 45.30% at year end.

From the 2025 annual report

Staff: 250 (149 men, 101 women), of whom 9 on fixed-term contracts. Total pay for the year: ₩13.4B. Directors and auditors: 6, paid ₩508M in total.

No cash dividend was paid for 2025.

Largest shareholder

삼천당제약(주) holds 44.50%; with 1 related party the group holds 45.30% of common shares at year end (from 40.20% at the start of the year).

Auditor: 선진회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary